Imexpharm

Imexpharm Gross Margin

The Gross Margin of Imexpharm (IMP.VN) as of Oct 26, 2026 is 41.03 %. In the previous year, Gross Margin was 38.80 % — a change of 5.75% (higher).

Gross Margin

41.03 %

YoY

5.75%

Last updated:

Gross Margin of Imexpharm is 2025 41.03 % . Gross Margin of Imexpharm was 2024 38.80 % . It decreases by 5.75% higher compared to the previous year.

Imexpharm's gross margin stands at 41.0%, up from 38.5% several years earlier.

The Imexpharm Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
39.64 VND
Jan 1, 2019
37.64 VND
Jan 1, 2020
39.95 VND
Jan 1, 2021
38.53 VND
Jan 1, 2022
42.43 VND
Jan 1, 2023
40.65 VND
Jan 1, 2024
38.80 VND
Jan 1, 2025
41.03 VND
The Imexpharm Gross Margin history
YEARGross MarginYoY
41.03 %+5.75%
38.80 %-4.55%
40.65 %-4.19%
42.43 %+10.12%
38.53 %-3.55%
39.95 %+6.12%
37.64 %-5.03%
39.64 %+5.75%
37.48 %-6.51%
40.09 %+0.87%
39.74 %-14.88%
46.69 %+9,975.86%
0.46 %+0.40%
0.46 %-7.63%
0.50 %+8.18%
0.46 %+3.91%
0.44 %+3.19%
0.43 %+0.78%
0.43 %+42.01%
0.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

Gross Margin of Imexpharm is 41.03 % in 2025.

Gross Margin of Imexpharm changed from 38.80 % to 41.03 %, representing a 5.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Imexpharm since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Imexpharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Imexpharm

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Imexpharm